Technology Bundle ID
TAB-3513

Development Dual Flt3/IRAK Inhibitors for the Treatment of Cancer

Applications
Linked ID
E-262-2016-0
Lead Inventors
Daniel Starczynowski (Cincinnati Children's Hospital Medical Center)
Co-Inventors
Craig Thomas (NCATS)
Garrett Rhyasen (Cincinnati Children's Hospital Medical Center)
Jian-kang Jiang (NCATS)
Katelyn Melgar (University of Cincinnati)
Morgan Walker (Yale University)
ICs
This technology includes a class of 3-(pyridin-2-yl)imidazo[1,2-a]pyridines that acts as a dual inhibitor of Flt3 and IRAK for the treatment of cancer. Acute myeloid leukemia (AML) remains associated with poor outcomes despite advances in our understanding of the complicated molecular events driving leukemogenesis and malignant progression. Those patients harboring mutations in the FLT3 receptor tyrosine kinase have a particularly poor prognosis; however, treatment targeting FLT3 mutations has failed to achieve robust and sustained clinical responses. We have recently identified the secondary adaptor kinase IRAK as being one key element of this resistance. In parallel, we found that a class of 3-(pyridin-2- yl)imidazo[1,2-a]pyridines has dual activity versus Flt3 and IRAK kinases and a superior anticancer profile relative to Flt3-only inhibitors.
Commercial Applications
Further clinical work could establish a dual inhibitor of Flt3 and IRAK for the treatment of cancer, including acute myeloid leukemia (AML).
Competitive Advantages
The dual-targeting of both Flt3 and IRAK appears to provide a superior anti-cancer outcome.

Request More Info

Licensing Contact: